Galecto (GLTO) Revenue & Revenue Breakdown
Galecto Revenue Highlights
Galecto Revenue by Period
Galecto Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | - |
Galecto generated - in revenue during NA 2023, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Galecto Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | - | 100.00% |
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $1.20M | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | - |
Galecto generated - in revenue during Q2 2024, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Galecto Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| AMLX | Amylyx Pharmaceuticals | $380.79M | $88.64M |
| CHRS | Coherus BioSciences | $257.24M | $64.98M |
| SPRO | Spero Therapeutics | $96.73M | $10.20M |
| AADI | Aadi Bioscience | $24.35M | $6.18M |
| ALGS | Aligos Therapeutics | $15.53M | - |
| RVMD | Revolution Medicines, Inc. Warrant | $11.58M | - |
| BOLT | Bolt Biotherapeutics | $7.88M | $1.27M |
| MOLN | Molecular Partners | $7.04M | $2.74M |
| CNTA | Centessa Pharmaceuticals | $6.88M | - |
| LYEL | Lyell Immunopharma | $130.00K | $3.00K |
| CGEM | Cullinan Oncology | - | - |
| GRCL | Gracell Bio | - | - |
| DAWN | Day One Biopharmaceuticals | - | $8.19M |
| ABOS | Acumen Pharmaceuticals | - | - |
| CYT | Cyteir Therapeutics | - | - |
| NLTX | Neurogene | - | - |
| TERN | Terns Pharmaceuticals | - | - |
| GLTO | Galecto | - | - |
| ACRV | Acrivon Therapeutics | - | - |
| GLUE | Monte Rosa Therapeutics | - | $4.70M |
| EWTX | Edgewise Therapeutics | - | - |
| MLTX | MoonLake Immunotherapeutics | - | - |
GLTO Revenue FAQ
What is Galecto’s yearly revenue?
Galecto's yearly revenue for 2023 was $0, representing an increase of 100.00% compared to 2022. The company's yearly revenue for 2022 was $0, representing an increase of 100.00% compared to 2021. GLTO's yearly revenue for 2021 was $0, representing an increase of 100.00% compared to 2020.
What is Galecto’s quarterly revenue?
Galecto's quarterly revenue for Q2 2024 was $0, a 100.00% increase from the previous quarter (Q1 2024), and a 0% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $0, a -100.00% decrease from the previous quarter (Q4 2023), and a 0% increase year-over-year (Q1 2023). GLTO's quarterly revenue for Q4 2023 was $1.2M, a 100.00% increase from the previous quarter (Q3 2023), and a 0% increase year-over-year (Q4 2022).
What is Galecto’s revenue growth rate?
Galecto's revenue growth rate for the last 3 years (2021-2023) was 0%, and for the last 5 years (2019-2023) was 0%.